Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization.
about
Malaria vaccine: a future hope to curtail the global malaria burdenThe March Toward Malaria VaccinesT cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian childrenPeripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria vaccine: analysis of pooled phase II clinical trial data.Community engagement in biomedical research in an African setting: the Kintampo Health Research Centre experienceDevelopment of newborn and infant vaccinesThe RTS,S vaccine candidate for malaria.Genetic variation in the Plasmodium falciparum circumsporozoite protein in India and its relevance to RTS,S malaria vaccine.A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malariaExtended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial.The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infantsDesign of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa.Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccineDesign considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigensUse of Antimalarial in the Management of Fever during a Community Survey in the Kintampo Districts of Ghana.Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic regionGenetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria VaccineSepsis, parenteral vaccination and skin disinfection.Nanocarriers: a versatile approach for mucosal vaccine delivery.The march toward malaria vaccines.Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials.Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum.The RTS,S/AS01 malaria vaccine in children 5 to 17 months of age at first vaccination.Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trialLe vaccin antipaludique RTS,S/AS01 chez les enfants âgés de 5 à 17 mois au moment de la première vaccination
P2860
Q26996425-021933FD-E236-45CC-8DA9-EB1912A512A9Q28084325-BF15D682-C1CC-4E63-B3AA-50A7FAA0AA7AQ28740701-7F9BE830-5339-4C33-8E06-3A1F59506D6FQ30662529-051CFEB7-E7C8-4004-9B25-4F75BD50FAA6Q33590277-C53B1486-73DC-4BC7-92B6-BA65520B4C4AQ33941914-78D55833-67B7-41C3-83C2-12E7F4CA0275Q34186762-631B0AC3-5E4C-4EC2-B379-DAB9D994B586Q34389610-B788909E-5032-4B2A-AC28-79AC50608059Q34469817-B63AF848-7E54-4B13-A864-6E4DAC4C5FDDQ35048336-B478828C-91F4-44D9-9B52-55DD4AB4693BQ35105075-D74B1E5B-2DAB-4F50-9DEB-DE6EB365B8FCQ35428630-5D73527D-6E37-440A-BAD8-645EFA03C1F8Q35563056-07818714-53C3-4F53-9096-E48DD8E59F65Q35812875-094B33FB-02E5-4370-8253-7670AEF154BEQ35844914-A058C566-AE4B-40F6-98F9-5F1F7A415C33Q36568190-C7AA6ACA-F9F9-483A-8801-9934BD39A22DQ36603519-CE52DB62-B386-4A1A-AB06-D882AA8D1083Q37375883-06AEE33B-AA06-4AD9-A8B2-1BEFCB083D1AQ38358876-4702AC2D-E111-43E8-9330-1629B949401FQ38577638-DA1329AF-7146-4AF3-915A-C7BDE5FA561CQ38599514-DC8E6914-67D0-41F1-A473-178B133F03AFQ42126049-36FEC696-A29D-4081-9733-81F4D2AA7617Q47977891-ED1CFF9E-6543-4700-8DE7-33DF862D0923Q56337574-99186007-A3DF-4734-8105-BDD3D02D7D1BQ58131059-5EBCC43B-9430-427E-B4A1-53162427D666
P2860
Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Evaluation of the safety and i ...... anded program of immunization.
@en
type
label
Evaluation of the safety and i ...... anded program of immunization.
@en
prefLabel
Evaluation of the safety and i ...... anded program of immunization.
@en
P2093
P50
P356
P1476
Evaluation of the safety and i ...... anded program of immunization.
@en
P2093
Amanda Leach
Barbara Savarese
Blaise Okissi
David Dosoo
Didier Lapierre
Erik Jongert
Evans Kwara
George Adjei
Grace Mwangoka
P304
P356
10.1086/656190
P407
P50
P577
2010-10-01T00:00:00Z